The new CEO of Stoke Therapeutics, Ian Smith, discusses Stoke Therapeutics' Dravet syndrome therapy, which caught much attention after publishing phase 1/2 data in NEJM last month

He describes how Stoke aims to up-regulate healthy genes in cases where diseases are caused by autosomal dominant haploinsufficiencies, like Dravet. He discusses the phase 1/2 data, a phase 3 that is scheduled to read out in 2027, and the regulatory history of the program.